Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Conditions:   Stage II-IVB Operable HNSCC Oral Cavity;   Hypopharynx;   Oropharynx;   Larynx
Interventions:   Drug: Durvalumab;   Drug: durvalumab + tremelimumab
Sponsor:   Yonsei University
Not yet recruiting

https://ift.tt/2qL8jn4